15 results about "Helminths" patented technology

This item is a lure (worm) used for octopus fishing. It is made of a flexible material and shaped to resemble a crustacean such as a crayfish. It is used attached to a hook rig, for example, as shown in the "Reference Diagram Showing the Names of Each Part." In this example, the hook rig consists of a core rod with a fishing hook, a ball, and a worm attachment rod. This item has a hook rig attachment hole, as shown in the "AA Cross-Sectional View." Therefore, as shown in the "Reference Perspective View from the Rear Side Showing the Usage State," the worm attachment rod is passed through the hook rig attachment hole, and the hook at the tip of the worm attachment rod is hooked onto the core rod, thereby attaching the item to the hook rig. As shown in red in the "Reference Diagram Showing Air Pockets," air is trapped inside the areas corresponding to the claws and tail. Therefore, during use, buoyancy in the sea tends to cause the air pockets to face upwards. Therefore, when it lies on the seabed (with the longitudinal direction of the needle arrangement aligned with the seabed), the surface shown in the front view tends to face upwards, and the surface shown in the rear view tends to face downwards (towards the seabed). In other words, when viewed from above, the item is likely to land in the state shown in the front view. Moreover, the claws are raised, mimicking the intimidation behavior of crustaceans.

A method of mitigating and rehabilitating soil and land areas contaminated with forever chemicals such as PFAS (perfluoroalkyl and polyfluoroalkyl) based toxins involves manipulating genetic nucleotides of carrier organisms for expressing an enzyme reactive with the forever chemicals for rendering them benign. The carrier organisms pass the modified DNA that enables the enzyme to subsequent generations for maintaining an active population of enzyme-expressing organisms, typically worms, once introduced.

The present invention is related to the recombinant production of proteins by using a synthetic gene for high protein expression in Pichia pastoris. More specifically, the invention describes the production of Sm14 Schistosoma mansoni recombinant protein, where a synthetic gene was created to promote high expression of such protein, a gene which was cloned under control of two types of Pichia pastoris promoters: methanol-inducible promoter (AOXI) and constituent promoter (GAP). With these constructions, Pichia pastoris strains were genetically manipulated to efficiently produce vaccine antigen Sm14. The processes to produce and purify this protein from P. pastoris cells, which can be escalated for their industrial production, were also improved.

Systems, devices, and methods for managing air gaps in a semiconductor device are provided. In one aspect, a method includes removing coelomic fluid from an exterior surface of the worms using a drying agent; removing blood from the worms; performing centrifugation on the blood to generate a blood supernatant; concentrating, by a tangential flow filtration system with a single membrane, the blood supernatant to form a concentrated blood product; and performing, by the tangential flow filtration system, tangential flow filtration of a diafiltration mixture comprising the concentrated blood product.

A fixative contains carboxylic acid, preferably acetic acid, for parasitological samples. An exemplary aqueous fixative solution for parasitological samples comprises: a) a C2 to C6 carboxylic acid (preferably acetic acid) at a concentration of 0.5M or greater; and b) a C2 to C6 carboxylate salt or halide salt at a concentration of 0.02M or greater, preferably 0.04M or greater. An optional composition comprises 1.3M acetic acid, 12 mM sodium benzoate, 0.9% calcium chloride, 0.9% calcium bromide, 100 μg / ml menthol and 350 μg / ml thymol. The fixative is free of formaldehyde or other hazardous compounds, and exhibits good killing and staining properties when used with parasitological samples such as ova and helminths.

This invention provides the application of Usnea powder, Usnea acid, or sodium usneate (or Usnea powder, Usnea acid, or sodium usneate as the sole active ingredient) in the preparation of broad-spectrum antiparasitic drugs for aquatic animals, drugs for treating complications caused by parasitic infections, feed additives, or functional feeds. By utilizing Usnea, Usnea extract, Usnea acid, and Usnea salts, various parasites, including ciliates, worms, and protozoa, that infest the surface and interior of aquatic animals during aquaculture can be eliminated or killed, thus maintaining the health of farmed animals, improving the success rate of aquaculture, achieving broad-spectrum and highly effective prevention and control of aquatic animal parasitic diseases, reducing the use of chemical drugs, and providing good aquaculture, ecological, and social benefits. It is safe, broad-spectrum, and highly effective, facilitating large-scale promotion.

A method of mitigating and rehabilitating soil and land areas contaminated with forever chemicals such as PFAS (perfluoroalkyl and polyfluoroalkyl) based toxins involves manipulating genetic nucleotides of carrier organisms for expressing an enzyme reactive with the forever chemicals for rendering them benign. The carrier organisms pass the modified DNA that enables the enzyme to subsequent generations for maintaining an active population of enzyme-expressing organisms, typically worms, once introduced.

Described herein are compositions and methods for the treatment or prevention of dermal or ocular surface disorders, such as those associated with bacterial and / or parasitic infections. Bacterial and / or parasitic infections include mites (e.g., demodex), worms, protozoa (e.g., amoeba (e.g., acanthamoeba or cryptosporidiosis)), onchocerciasis, lice, scabies, nematodes, or chlamydia. Said compositions and methods comprise compounds which demonstrate immunological, keratolytic, anti-histamine, anti-inflammatory, and / or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

The invention discloses an application of kochia saponin in preparation of a medicine for treating helminthosis, an in-vitro effectiveness experiment result of the kochia saponin on an echinococcosis multilocularis protoscolex shows that the killing effect of the kochia saponin on the protoscolex has time and concentration dependence, the death rates of 10 [mu] M, 20 [mu] M and 50 [mu] M of kochia saponin treated for 6 h are 8.05% + / -0.39%, 89.23% + / -1.48% and 100% respectively, and the death rates of 10 [mu] M, 20 [mu] M and 50 [mu] M of kochia saponin treated for 24 h are all 100%; meanwhile, results of in-vitro effectiveness experiments of kochia saponin on trichina at different development stages show that after the trichina is treated for 72 hours under the concentration of 50 mu M, 80 mu M and 100 mu M, the death rates of muscular larvae are 86.24% + / -1.15%, 90.17% + / -1.24% and 90.86% + / -2.10% respectively; after treatment for 24 hours, the death rates of the newborn larvae are respectively 12.71% + / -2.36%, 57.80% + / -2.23% and 79.60% + / -1.52%, all the newborn larvae die after 48 hours, and the killing effect is obvious. Besides, the applicant confirms that the mogroside can directly destroy the epidermis structure and cell integrity of the insect body for the first time through microscope observation, and the discovery provides visual morphological evidence for the anti-parasitic effect of the mogroside.

This invention provides for compounds of the formula:wherein the variables are defined herein, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, or salt thereof, compositions comprising these compounds, and method for the treatment, control or prevention of a parasitic infestation or infection in an animal in need thereof by administering an effective amount of these compounds to said animal.

The present disclosure is directed to methods for preventing or treating helminth (e.g., filarial) diseases in animals. The methods are accomplished by administering to the animal a therapeutically effective amount of an inhibitor of UDP-glucoronosyl transferase (UGT) or immunoglobulin I-set domain containing protein (Igl-DCP, also known as BMA-Lad-2). The inhibitors include those known to inhibit glucuronyltransferase enzyme activity as well as cell adhesion molecule inhibitors and antibodies specific for Igl-DCP and / or UGT.

The invention discloses an application of psoralen B in preparation of a medicine for treating helminthosis, an in-vitro effectiveness experiment result of psoralen B on an echinococcosis multilocularis protoscolex shows that the killing effect of maduramicin ammonium on the protoscolex has concentration dependence, the death rate of the protoscolex can reach 90.63% + / -0.96% after the maduramicin ammonium is treated for 6 h at the concentration of 50 mu M, and the death rate of the protoscolex can reach 90.63% + / -0.96% at the concentration of 100 mu M, and the death rate of the maduramicin ammonium can reach 90.63% + / -0.96% at the concentration of 100 mu M. The death rate of the original head section can directly reach 100%; meanwhile, in-vitro effectiveness experiment results of psoralen B on trichina at different development stages show that after the trichina is treated for 72 hours under the concentration of 50 mu M, 80 mu M and 100 mu M, the death rates of muscular larvae reach 89.44% + / -0.81%, 96.29% + / -1.30% and 96.68% + / -1.06% respectively; after 48 hours of treatment, the death rate of the adults is 100%, and the killing effect is remarkable. More importantly, the applicant verifies that IBC can directly destroy the epidermal structure and cell integrity of the insect body for the first time through observation by an optical microscope and an electron microscope, and the discovery provides intuitive morphological evidence for the anti-parasitic effect of IBC.

Described herein are compositions and methods for the treatment or prevention of dermal or ocular surface disorders, such as those associated with bacterial and / or parasitic infections. Bacterial and / or parasitic infections include mites (e.g., demodex), worms, protozoa (e.g., amoeba (e.g., acanthamoeba or cryptosporidiosis)), onchocerciasis, lice, scabies, nematodes, or chlamydia. Said compositions and methods comprise compounds which demonstrate immunological, keratolytic, anti-histamine, anti-inflammatory, and / or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

The present invention relates to use of the Sm14 protein as a vaccine antigen against parasites of the phylum Nematoda, also known as nemathelminths or nematodes. In addition to its use against flatworm infections, such as Schistosoma sp, Fasciola sp. and Haemonchus contortus, the present invention also includes compositions containing Sm14 protein, FhFABP-3 protein, and LBP-4 to protect canine, feline, ovine, and ruminant animals from diseases caused by nematodes such as Dirofilaria immitis and Haemonchus contortus.

The present disclosure relates to a cleaning apparatus for cleaning live insects, in particular live insect larvae, or live worms, the cleaning apparatus comprising a collecting device for receiving the insects or worms and mixing them with water, forming a mixture, a first conveying device for conveying the mixture from the collecting device, and a first larvae separating device for separating the insects or worms from the water of the mixture conveyed by the first conveying device. The separated water can be further used in the insect apparatus, in particular the cleaning apparatus, in particular at least partially recirculated in the cleaning apparatus.